JP Morgan Maintains Overweight on Travere Therapeutics, Raises Price Target to $23
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Anupam Rama maintains an Overweight rating on Travere Therapeutics and raises the price target from $20 to $23.
September 13, 2024 | 7:26 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
JP Morgan's analyst Anupam Rama has maintained an Overweight rating on Travere Therapeutics and increased the price target from $20 to $23, indicating a positive outlook on the stock.
The increase in price target from $20 to $23 by a reputable analyst at JP Morgan suggests a positive outlook for Travere Therapeutics. This is likely to boost investor confidence and potentially lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100